iOnctura Strengthens Management With Appointment of Sean A. MacDonald as Chief Business Officer GENEVA, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today...

iOnctura Boosts Management Team With Appointment of David Seeberger as VP Finance GENEVA, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today...

iOnctura Project Evaluating Novel PI3Kδ-inhibitor IOA-244 in Lymphoma to be Co-funded by Innosuisse Project to investigate novel combination therapies in lymphoma with IOA-244IOA-244 Phase 1b clinical development in solid tumors initiated GENEVA, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) --...

iOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin Inhibitor IOA-289 Safety, pharmacokinetic and pharmacodynamic readouts expected Q4 2021IOA-289 first ATX inhibitor to progress to clinic in oncology GENEVA, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- iOnctura...